(Editor’s Note: This exclusive post is from one of our distinguished Advisory Board members, Andrew Schorr, author, medical journalist and cancer survivor. Andrew is currently living in Barcelona, Spain, and reporting to us from there.)
(Editor’s Note: This exclusive post is from one of our distinguished Advisory Board members, Andrew Schorr, author, medical journalist and cancer survivor. Andrew is currently living in Barcelona, Spain, and reporting to us from there.)
It is an “exciting” time on many levels in modern medicine, especially when it comes to the treatment of a number of cancers. So called “small molecule, targeted therapies, are being approved by the FDA and more are coming, even anointed with “breakthrough” status. For patients with conditions like chronic lymphocytic leukemia (CLL), a condition I was successfully treated for a number of years ago, there are new pills coming that are expected to greatly help even the sickest patients. Extending lives and returning many people to a high quality of life. The same has happened in other leukemias, lymphomas, myeloma, some lung cancers, some breast cancers, and advanced melanoma. Pharnaceutical researchers have been figuring out how to turn off mutated genes that fuel cancer cell growth or prevent a cancer cell from dying. The science is very cool and the impact for patients is great.
But there’s a looming impact on our healthcare costs too. Here’s a very personal example. About a year ago I was diagnosed with a second cancer, myelofibrosis or early scarring in my bone marrow. Maybe it came from my earlier leukemia, maybe from the chemo I had years ago. Maybe not. No one knows. But the good news is there is a breakthrough new class of medicines that reverses the bad symptoms, like enlarged spleen, and the first approved medicine, a twice daily pill, allows me to lead a very full life. No symptoms and new evidence, in a just released study, of extended survival. What’s the downside? The cost is $7,700 a month. Thank God I have insurance that pays for it!
